Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-center, observational real-world study: evaluating the efficacy of pembrolizumab combined with standard chemotherapy (cisplatin/carboplatin + paclitaxel) in the first-line treatment of locally recurring head and neck squamous cell carcinoma under different TP53 and PIK3CA states and safety

Next Previous
Search
Trial Profile

A prospective, single-center, observational real-world study: evaluating the efficacy of pembrolizumab combined with standard chemotherapy (cisplatin/carboplatin + paclitaxel) in the first-line treatment of locally recurring head and neck squamous cell carcinoma under different TP53 and PIK3CA states and safety

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jul 2023 New trial record
    • 06 Jun 2023 Results (n=20; From January 8, 2020 until September 20 2022) assessing the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in patients locally recurrent head and neck squamous cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top